CA2327708A1 - Antioxidant stabilizer system for pharmaceutical formulations - Google Patents

Antioxidant stabilizer system for pharmaceutical formulations Download PDF

Info

Publication number
CA2327708A1
CA2327708A1 CA002327708A CA2327708A CA2327708A1 CA 2327708 A1 CA2327708 A1 CA 2327708A1 CA 002327708 A CA002327708 A CA 002327708A CA 2327708 A CA2327708 A CA 2327708A CA 2327708 A1 CA2327708 A1 CA 2327708A1
Authority
CA
Canada
Prior art keywords
acid
carboxylic acid
hydrogen
alkyl
organic carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002327708A
Other languages
English (en)
French (fr)
Inventor
Philip C. Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roberts Laboratories Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2327708A1 publication Critical patent/CA2327708A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
CA002327708A 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations Abandoned CA2327708A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,260 1998-04-08
US09/057,260 US5962488A (en) 1998-04-08 1998-04-08 Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
PCT/US1998/024471 WO1999052529A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CA2327708A1 true CA2327708A1 (en) 1999-10-21

Family

ID=22009506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327708A Abandoned CA2327708A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Country Status (7)

Country Link
US (2) US5962488A (https=)
EP (1) EP1067927B1 (https=)
JP (1) JP2003522724A (https=)
AT (1) ATE318598T1 (https=)
CA (1) CA2327708A1 (https=)
DE (1) DE69833684T2 (https=)
WO (1) WO1999052529A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
WO2000042997A1 (en) * 1999-01-21 2000-07-27 Shionogi & Co., Ltd. Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007046411A1 (ja) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. イソキサゾール化合物の安定化方法
DE102007025275A1 (de) * 2007-05-31 2008-12-04 Qiagen Gmbh Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2309985B1 (en) * 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
BR112017027855B1 (pt) * 2015-06-23 2022-11-16 Intervet International B.V. Composição farmacêutica, seu uso, água potável medicamentosa e método para sua preparação
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP4221704B1 (en) * 2020-10-01 2025-09-24 Imago Biosciences Inc. Pharmaceutical formulations for treating diseases mediated by kdm1a

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB679192A (en) * 1948-07-09 1952-09-17 Eastman Kodak Co Method of stabilizing fats and fatty oils against oxidation
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
JPS5299242A (en) * 1976-02-12 1977-08-19 Tanabe Seiyaku Co Antiioxidant
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
US5077069A (en) * 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
JPH06500594A (ja) * 1991-01-07 1994-01-20 カビ　ファルマシア　アクチェボラーグ 多不飽和油の安定化のための天然酸化防止剤の組成物
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
CA2173467A1 (en) * 1993-10-25 1995-05-04 Keith D. Ertel A stable pharmaceutical composition of terfenadine and ibuprofen
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JP3941073B2 (ja) * 1996-03-01 2007-07-04 日本油脂株式会社 油脂組成物及びそれを含む食品
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Also Published As

Publication number Publication date
ATE318598T1 (de) 2006-03-15
EP1067927A1 (en) 2001-01-17
US5962488A (en) 1999-10-05
EP1067927B1 (en) 2006-03-01
EP1067927A4 (en) 2003-04-23
JP2003522724A (ja) 2003-07-29
WO1999052529A1 (en) 1999-10-21
DE69833684D1 (de) 2006-04-27
US6479529B1 (en) 2002-11-12
DE69833684T2 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
CA2327708A1 (en) Antioxidant stabilizer system for pharmaceutical formulations
CA1297024C (en) Drug compositions stabilized against oxidation
JP2619904B2 (ja) 安定化された組成物
EP0840603B1 (en) Pharmaceutical composition of l-dopa ethyl ester
US20080075773A1 (en) New Oral Formulation
EA000976B1 (ru) Композиция для снятия боли и способ снятия боли
AP324A (en) Medicaments for treating inflammatory conditions or for analgiesia.
WO2000028993A1 (en) Serotonin ligands as pro-erectile compounds
CA2432644A1 (en) Pharmaceutical composition comprising aspirintm and cs-747
EA008108B1 (ru) Комбинация нспвлс и ингибитора pde-4
HUT71477A (en) Pharmaceutical compositions for increasing libido in post-menopausal women containing 2-phenyl-3-aroil-benzothiophene derivatives and process for their preparation
EP1588707A1 (en) Stable solid medicinal composition for oral administration
HUT71329A (en) Pharmaceutical compositions for inhibiting cns problems in post-menopausal women containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US5002946A (en) Phenylethanolamine analog active compounds for the treatment of gastrointestinal diseases
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
US4465692A (en) Selective D-2 dopamine receptor agonist
US20030212050A1 (en) Prophylactic treatment of migraine
US5270341A (en) Method of treatment or prophylaxis of depression and stress
WO2011126327A2 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
JP3254712B2 (ja) 医薬組成物
ZA200500064B (en) Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
HUT77381A (hu) Eljárás növekedési hormonok hatásainak inhibiálására alkalmas benzotiofén-származékokat tartalmazó gyógyszerkészítmények előállítására
KR20240128504A (ko) 산 펌프 억제 활성을 갖는 신규 벤즈이미다졸 유도체
KR20250034266A (ko) 설트랄린 또는 이의 염을 포함하는 약학적 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued